The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Epigenetics Drugs and Diagnostic Technologies-Global Market Insights and Sales Trends 2024

Epigenetics Drugs and Diagnostic Technologies-Global Market Insights and Sales Trends 2024

Publishing Date : Dec, 2023

License Type :
 

Report Code : 1860490

No of Pages : 122

Ask Your Query

Synopsis

The global Epigenetics Drugs and Diagnostic Technologies market size is expected to reach US$ 27650 million by 2029, growing at a CAGR of 17.1% from 2023 to 2029. The market is mainly driven by the significant applications of Epigenetics Drugs and Diagnostic Technologies in various end use industries. The expanding demands from the Non coding RNA’s, Micro RNA’s, Histone modifications and DNA methylation, are propelling Epigenetics Drugs and Diagnostic Technologies market. HDAC inhibitors, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the DNMT inhibitors segment is estimated at % CAGR for the next seven-year period.

Asia Pacific shows high growth potential for Epigenetics Drugs and Diagnostic Technologies market, driven by demand from China, the second largest economy with some signs of stabilising, the Epigenetics Drugs and Diagnostic Technologies market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.

Report Objectives

This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Epigenetics Drugs and Diagnostic Technologies, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.

Key Features of The Study:

This report provides in-depth analysis of the global Epigenetics Drugs and Diagnostic Technologies market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.

This report profiles key players in the global Epigenetics Drugs and Diagnostic Technologies market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Epigenetics Drugs and Diagnostic Technologies sales data, market share and ranking.

This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.

This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.

Key companies of Epigenetics Drugs and Diagnostic Technologies covered in this report include Varlix Plc, Topotarget, Syndax Pharmaceuticals, Spectrum Pharmaceuticals, Promega, Novartis, Oncolys BioPharma, MDxHealth and Merck, etc.

The global Epigenetics Drugs and Diagnostic Technologies market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.

Market Segmentation

Company Profiles:

  • Varlix Plc
  • Topotarget
  • Syndax Pharmaceuticals
  • Spectrum Pharmaceuticals
  • Promega
  • Novartis
  • Oncolys BioPharma
  • MDxHealth
  • Merck
  • Illumina
  • Epizyme
  • Forum Pharmaceuticals
  • EpiGentek
  • Chroma Therapeutics
  • Celleron Therapeutics
  • CellCentric
  • Astex Pharmaceuticals
  • Acetylon Pharmaceuticals
  • 4SC AG
  • Eisai
  • Pharmacyclics

Global Epigenetics Drugs and Diagnostic Technologies market, by region:

  • North America (U.S., Canada, Mexico)
  • Europe (Germany, France, UK, Italy, etc.)
  • Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
  • South America (Brazil, etc.)
  • Middle East and Africa (Turkey, GCC Countries, Africa, etc.)

Global Epigenetics Drugs and Diagnostic Technologies market, Segment by Type:

  • HDAC inhibitors
  • DNMT inhibitors

Global Epigenetics Drugs and Diagnostic Technologies market, by Application

  • Non coding RNA’s
  • Micro RNA’s
  • Histone modifications
  • DNA methylation

Core Chapters

Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Epigenetics Drugs and Diagnostic Technologies companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion

Index

1 Market Overview of Epigenetics Drugs and Diagnostic Technologies
1.1 Epigenetics Drugs and Diagnostic Technologies Market Overview
1.1.1 Epigenetics Drugs and Diagnostic Technologies Product Scope
1.1.2 Epigenetics Drugs and Diagnostic Technologies Market Status and Outlook
1.2 Global Epigenetics Drugs and Diagnostic Technologies Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Epigenetics Drugs and Diagnostic Technologies Market Size by Region (2018-2029)
1.4 Global Epigenetics Drugs and Diagnostic Technologies Historic Market Size by Region (2018-2023)
1.5 Global Epigenetics Drugs and Diagnostic Technologies Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Epigenetics Drugs and Diagnostic Technologies Market Size (2018-2029)
1.6.1 North America Epigenetics Drugs and Diagnostic Technologies Market Size (2018-2029)
1.6.2 Europe Epigenetics Drugs and Diagnostic Technologies Market Size (2018-2029)
1.6.3 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Market Size (2018-2029)
1.6.4 Latin America Epigenetics Drugs and Diagnostic Technologies Market Size (2018-2029)
1.6.5 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Market Size (2018-2029)
2 Epigenetics Drugs and Diagnostic Technologies Market by Type
2.1 Introduction
2.1.1 HDAC inhibitors
2.1.2 DNMT inhibitors
2.2 Global Epigenetics Drugs and Diagnostic Technologies Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Epigenetics Drugs and Diagnostic Technologies Historic Market Size by Type (2018-2023)
2.2.2 Global Epigenetics Drugs and Diagnostic Technologies Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Type (2018-2029)
3 Epigenetics Drugs and Diagnostic Technologies Market Overview by Application
3.1 Introduction
3.1.1 Non coding RNA’s
3.1.2 Micro RNA’s
3.1.3 Histone modifications
3.1.4 DNA methylation
3.2 Global Epigenetics Drugs and Diagnostic Technologies Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Epigenetics Drugs and Diagnostic Technologies Historic Market Size by Application (2018-2023)
3.2.2 Global Epigenetics Drugs and Diagnostic Technologies Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Epigenetics Drugs and Diagnostic Technologies Revenue Breakdown by Application (2018-2029)
4 Epigenetics Drugs and Diagnostic Technologies Competition Analysis by Players
4.1 Global Epigenetics Drugs and Diagnostic Technologies Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Epigenetics Drugs and Diagnostic Technologies as of 2022)
4.3 Date of Key Players Enter into Epigenetics Drugs and Diagnostic Technologies Market
4.4 Global Top Players Epigenetics Drugs and Diagnostic Technologies Headquarters and Area Served
4.5 Key Players Epigenetics Drugs and Diagnostic Technologies Product Solution and Service
4.6 Competitive Status
4.6.1 Epigenetics Drugs and Diagnostic Technologies Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Varlix Plc
5.1.1 Varlix Plc Profile
5.1.2 Varlix Plc Main Business
5.1.3 Varlix Plc Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.1.4 Varlix Plc Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.1.5 Varlix Plc Recent Developments
5.2 Topotarget
5.2.1 Topotarget Profile
5.2.2 Topotarget Main Business
5.2.3 Topotarget Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.2.4 Topotarget Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.2.5 Topotarget Recent Developments
5.3 Syndax Pharmaceuticals
5.3.1 Syndax Pharmaceuticals Profile
5.3.2 Syndax Pharmaceuticals Main Business
5.3.3 Syndax Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.3.4 Syndax Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.3.5 Spectrum Pharmaceuticals Recent Developments
5.4 Spectrum Pharmaceuticals
5.4.1 Spectrum Pharmaceuticals Profile
5.4.2 Spectrum Pharmaceuticals Main Business
5.4.3 Spectrum Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.4.4 Spectrum Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.4.5 Spectrum Pharmaceuticals Recent Developments
5.5 Promega
5.5.1 Promega Profile
5.5.2 Promega Main Business
5.5.3 Promega Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.5.4 Promega Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.5.5 Promega Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.6.4 Novartis Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Oncolys BioPharma
5.7.1 Oncolys BioPharma Profile
5.7.2 Oncolys BioPharma Main Business
5.7.3 Oncolys BioPharma Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.7.4 Oncolys BioPharma Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.7.5 Oncolys BioPharma Recent Developments
5.8 MDxHealth
5.8.1 MDxHealth Profile
5.8.2 MDxHealth Main Business
5.8.3 MDxHealth Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.8.4 MDxHealth Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.8.5 MDxHealth Recent Developments
5.9 Merck
5.9.1 Merck Profile
5.9.2 Merck Main Business
5.9.3 Merck Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.9.4 Merck Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.9.5 Merck Recent Developments
5.10 Illumina
5.10.1 Illumina Profile
5.10.2 Illumina Main Business
5.10.3 Illumina Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.10.4 Illumina Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.10.5 Illumina Recent Developments
5.11 Epizyme
5.11.1 Epizyme Profile
5.11.2 Epizyme Main Business
5.11.3 Epizyme Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.11.4 Epizyme Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.11.5 Epizyme Recent Developments
5.12 Forum Pharmaceuticals
5.12.1 Forum Pharmaceuticals Profile
5.12.2 Forum Pharmaceuticals Main Business
5.12.3 Forum Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.12.4 Forum Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.12.5 Forum Pharmaceuticals Recent Developments
5.13 EpiGentek
5.13.1 EpiGentek Profile
5.13.2 EpiGentek Main Business
5.13.3 EpiGentek Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.13.4 EpiGentek Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.13.5 EpiGentek Recent Developments
5.14 Chroma Therapeutics
5.14.1 Chroma Therapeutics Profile
5.14.2 Chroma Therapeutics Main Business
5.14.3 Chroma Therapeutics Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.14.4 Chroma Therapeutics Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.14.5 Chroma Therapeutics Recent Developments
5.15 Celleron Therapeutics
5.15.1 Celleron Therapeutics Profile
5.15.2 Celleron Therapeutics Main Business
5.15.3 Celleron Therapeutics Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.15.4 Celleron Therapeutics Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.15.5 Celleron Therapeutics Recent Developments
5.16 CellCentric
5.16.1 CellCentric Profile
5.16.2 CellCentric Main Business
5.16.3 CellCentric Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.16.4 CellCentric Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.16.5 CellCentric Recent Developments
5.17 Astex Pharmaceuticals
5.17.1 Astex Pharmaceuticals Profile
5.17.2 Astex Pharmaceuticals Main Business
5.17.3 Astex Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.17.4 Astex Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.17.5 Astex Pharmaceuticals Recent Developments
5.18 Acetylon Pharmaceuticals
5.18.1 Acetylon Pharmaceuticals Profile
5.18.2 Acetylon Pharmaceuticals Main Business
5.18.3 Acetylon Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.18.4 Acetylon Pharmaceuticals Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.18.5 Acetylon Pharmaceuticals Recent Developments
5.19 4SC AG
5.19.1 4SC AG Profile
5.19.2 4SC AG Main Business
5.19.3 4SC AG Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.19.4 4SC AG Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.19.5 4SC AG Recent Developments
5.20 Eisai
5.20.1 Eisai Profile
5.20.2 Eisai Main Business
5.20.3 Eisai Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.20.4 Eisai Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.20.5 Eisai Recent Developments
5.21 Pharmacyclics
5.21.1 Pharmacyclics Profile
5.21.2 Pharmacyclics Main Business
5.21.3 Pharmacyclics Epigenetics Drugs and Diagnostic Technologies Products, Services and Solutions
5.21.4 Pharmacyclics Epigenetics Drugs and Diagnostic Technologies Revenue (US$ Million) & (2018-2023)
5.21.5 Pharmacyclics Recent Developments
6 North America
6.1 North America Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Epigenetics Drugs and Diagnostic Technologies Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Epigenetics Drugs and Diagnostic Technologies Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Epigenetics Drugs and Diagnostic Technologies Market Dynamics
11.1 Epigenetics Drugs and Diagnostic Technologies Industry Trends
11.2 Epigenetics Drugs and Diagnostic Technologies Market Drivers
11.3 Epigenetics Drugs and Diagnostic Technologies Market Challenges
11.4 Epigenetics Drugs and Diagnostic Technologies Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock